Press Releases
Search
-
23 Oct 2013
Business Review for the Nine Months Ended September 30, 2013
Sales: 2013 objective confirmed Very good third quarter with sales up 7.4%* (5.7%* excluding R&D-related revenue) Robust organic growth of 3.9% over the first nine months (3.3% excluding R&D-related r...
-
07 Oct 2013
Successful placement of Inaugural €300-Million Issue of 7-Year Bonds
Marcy l'Etoile, France, October 7, 2013 - bioMérieux, a world leader in the field of in vitro diagnostics, announced the placement to institutional investors of its first issue of seven-year euro-bond...
-
30 Sept 2013
bioMérieux lance VIDAS® 25 OH Vitamine D TOTAL, un nouveau test pour le dosage de la vitamine D
Marcy l'Étoile, France, September 30, 2013 - bioMérieux, a world leader in the field of in vitro diagnostics, has announced the launch of VIDAS® 25 OH Vitamin D Total for the measurement of total vita...
-
03 Sept 2013
First-Half 2013 Results
Sales: €754 million, with a marked acceleration in the second quarter (+ 4%*) Operating income before non-recurring items in line with objectives: €125 million, or 16.6% of sales Major investments in ...
-
03 Sept 2013
bioMérieux makes a significant acquisition in molecular biology in the U.S.
With the acquisition of BioFire, bioMérieux consolidates its position as a major player in infectious disease diagnostics With a complete range of technologies for clinical microbiology diagnostics, b...
-
22 Aug 2013
bioMérieux Announces U.S. FDA Clearance for VITEK® MS, a Revolutionary Technology which Reduces Microbial Identification from Days to Minutes Reinforcing Medical Value of Diagnostics
Marcy L’Etoile (France) and Durham, NC - August 21, 2013 - bioMérieux today announced that it has been granted U.S. FDA 510(k) de novo clearance for VITEK® MS, the first clinical mass spectrometry MAL...